Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699319 · ClinicalTrials.gov registry record · Phase 1
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
A Phase 1 study, sponsored by David Bajor, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03699319 is a Phase 1 study that has completed, run by David Bajor, MD. The registered enrollment target is 49 participants.
The verdict
NCT03699319, a Phase 1 study, has completed, sponsored by David Bajor, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to treat participants with the combination of CPI-613 (the study drug) with FOLFIRINOX (the standard combination of drugs) to determine if it is safe and effective for participants with localized and unresectable pancreatic cancer. This study is specifically for participants who have a pancreatic cancer that is localized and not considered resectable or removable by a surgeon, without additional treatment.
Interventions
- DRUG Oxaliplatin
- DRUG Irinotecan
- DRUG Folinic acid
- DRUG CPI 613
- DRUG 5-flurouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2024-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03699319
The ClinicalTrials.gov registry entry for NCT03699319 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Bajor, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT03699319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03699319 about?
NCT03699319 is a clinical study titled "CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer". The purpose of this study is to treat participants with the combination of CPI-613 (the study drug) with FOLFIRINOX (the standard combination of drugs) to determine if it is safe and effective for participants with localized and unresectable pancreatic cancer. This study is specifically for particip...
What is the current status of trial NCT03699319?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-12-07. Estimated completion is 2024-09-23.
What interventions are being tested in trial NCT03699319?
The interventions under investigation include: Oxaliplatin (DRUG), Irinotecan (DRUG), Folinic acid (DRUG), CPI 613 (DRUG), 5-flurouracil (DRUG).
Who is sponsoring clinical trial NCT03699319?
This trial is sponsored by David Bajor, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.